27832159|t|A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet -Induced Obese C57BL/6J Mice
27832159|a|Obesity is now recognized as a state of chronic low-grade inflammation and is called as metabolic inflammation. Delta-5 desaturase (D5D) is an enzyme that metabolizes dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA). Thus, D5D inhibition increases DGLA (precursor to anti-inflammatory eicosanoids) while decreasing AA (precursor to pro-inflammatory eicosanoids), and could result in synergistic improvement in the low-grade inflammatory state. Here, we demonstrate reduced insulin resistance and the anti-obesity effect of a D5D selective inhibitor (compound-326), an orally active small-molecule, in a high-fat diet -induced obese (DIO) mouse model. In vivo D5D inhibition was confirmed by determining changes in blood AA / DGLA profiles. In DIO mice, chronic treatment with compound-326 lowered insulin resistance and caused body weight loss without significant impact on cumulative calorie intake. Decreased macrophage infiltration into adipose tissue was expected from mRNA analysis. Increased daily energy expenditure was also observed following administration of compound-326, in line with sustained body weight loss. These data indicate that the novel D5D selective inhibitor, compound-326, will be a new class of drug for the treatment of obese and diabetic patients.
27832159	18	27	Inhibitor	T103	UMLS:C0014432
27832159	31	49	Delta-5 Desaturase	T103	UMLS:C0057338
27832159	57	75	Insulin Resistance	T038	UMLS:C0021655
27832159	80	99	Reduces Body Weight	T033	UMLS:C1262477
27832159	103	107	Diet	T168	UMLS:C0012155
27832159	117	122	Obese	T038	UMLS:C0028754
27832159	123	136	C57BL/6J Mice	T204	UMLS:C1521751
27832159	137	144	Obesity	T038	UMLS:C0028754
27832159	195	207	inflammation	T038	UMLS:C0021368
27832159	235	247	inflammation	T038	UMLS:C0021368
27832159	249	267	Delta-5 desaturase	T103	UMLS:C0057338
27832159	269	272	D5D	T103	UMLS:C0057338
27832159	280	286	enzyme	T103	UMLS:C0014442
27832159	304	327	dihomo-γ-linolenic acid	T103	UMLS:C0000658
27832159	329	333	DGLA	T103	UMLS:C0000658
27832159	338	354	arachidonic acid	T103	UMLS:C0003695
27832159	356	358	AA	T103	UMLS:C0003695
27832159	367	370	D5D	T103	UMLS:C0057338
27832159	371	381	inhibition	T038	UMLS:C1524081
27832159	392	396	DGLA	T103	UMLS:C0000658
27832159	429	440	eicosanoids	T103	UMLS:C0013725
27832159	459	461	AA	T103	UMLS:C0003695
27832159	493	504	eicosanoids	T103	UMLS:C0013725
27832159	617	635	insulin resistance	T038	UMLS:C0021655
27832159	644	656	anti-obesity	T103	UMLS:C0376607
27832159	669	672	D5D	T103	UMLS:C0057338
27832159	694	706	compound-326	T103	UMLS:C1254351
27832159	712	718	orally	T082	UMLS:C0442027
27832159	726	740	small-molecule	T103	UMLS:C1328819
27832159	747	760	high-fat diet	T168	UMLS:C0453819
27832159	770	787	obese (DIO) mouse	T204	UMLS:C0025933
27832159	788	793	model	T038	UMLS:C0012644
27832159	803	806	D5D	T103	UMLS:C0057338
27832159	807	817	inhibition	T038	UMLS:C1524081
27832159	858	863	blood	T031	UMLS:C0005767
27832159	864	866	AA	T103	UMLS:C0003695
27832159	869	873	DGLA	T103	UMLS:C0000658
27832159	887	895	DIO mice	T204	UMLS:C0025933
27832159	920	932	compound-326	T103	UMLS:C1254351
27832159	941	959	insulin resistance	T038	UMLS:C0021655
27832159	971	987	body weight loss	T033	UMLS:C1262477
27832159	1055	1098	macrophage infiltration into adipose tissue	T033	UMLS:C4014887
27832159	1117	1130	mRNA analysis	T058	UMLS:C0872262
27832159	1148	1166	energy expenditure	T038	UMLS:C0014272
27832159	1195	1209	administration	T058	UMLS:C1533734
27832159	1213	1225	compound-326	T103	UMLS:C1254351
27832159	1250	1266	body weight loss	T033	UMLS:C1262477
27832159	1303	1306	D5D	T103	UMLS:C0057338
27832159	1317	1326	inhibitor	T103	UMLS:C0014432
27832159	1328	1340	compound-326	T103	UMLS:C1254351
27832159	1391	1396	obese	T038	UMLS:C0028754
27832159	1401	1409	diabetic	T038	UMLS:C0011847